Correlation Between Lotus Pharmaceutical and GeneFerm Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lotus Pharmaceutical and GeneFerm Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lotus Pharmaceutical and GeneFerm Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lotus Pharmaceutical Co and GeneFerm Biotechnology Co, you can compare the effects of market volatilities on Lotus Pharmaceutical and GeneFerm Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lotus Pharmaceutical with a short position of GeneFerm Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lotus Pharmaceutical and GeneFerm Biotechnology.

Diversification Opportunities for Lotus Pharmaceutical and GeneFerm Biotechnology

0.08
  Correlation Coefficient

Significant diversification

The 3 months correlation between Lotus and GeneFerm is 0.08. Overlapping area represents the amount of risk that can be diversified away by holding Lotus Pharmaceutical Co and GeneFerm Biotechnology Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GeneFerm Biotechnology and Lotus Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lotus Pharmaceutical Co are associated (or correlated) with GeneFerm Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GeneFerm Biotechnology has no effect on the direction of Lotus Pharmaceutical i.e., Lotus Pharmaceutical and GeneFerm Biotechnology go up and down completely randomly.

Pair Corralation between Lotus Pharmaceutical and GeneFerm Biotechnology

Assuming the 90 days trading horizon Lotus Pharmaceutical Co is expected to under-perform the GeneFerm Biotechnology. In addition to that, Lotus Pharmaceutical is 1.77 times more volatile than GeneFerm Biotechnology Co. It trades about -0.22 of its total potential returns per unit of risk. GeneFerm Biotechnology Co is currently generating about -0.3 per unit of volatility. If you would invest  5,010  in GeneFerm Biotechnology Co on September 24, 2024 and sell it today you would lose (290.00) from holding GeneFerm Biotechnology Co or give up 5.79% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Lotus Pharmaceutical Co  vs.  GeneFerm Biotechnology Co

 Performance 
       Timeline  
Lotus Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lotus Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Lotus Pharmaceutical is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
GeneFerm Biotechnology 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in GeneFerm Biotechnology Co are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, GeneFerm Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Lotus Pharmaceutical and GeneFerm Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lotus Pharmaceutical and GeneFerm Biotechnology

The main advantage of trading using opposite Lotus Pharmaceutical and GeneFerm Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lotus Pharmaceutical position performs unexpectedly, GeneFerm Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneFerm Biotechnology will offset losses from the drop in GeneFerm Biotechnology's long position.
The idea behind Lotus Pharmaceutical Co and GeneFerm Biotechnology Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data